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INTRODUCTION
Lymphoepithelial carcinoma (LEC) is a unique subset of head and neck 
squamous cell carcinoma, with a marked geographical variation is shown in 
incidence.  Although  LEC is  rare  worldwide,it  is  one  of  the  most  common 
cancers  in  South  East  Asian  countries  as  well  as  in  China,where  it  has  an 
incidence of 20-50 per 100 000 individuals1.
The  incidence  of  LEC  in    the  Indian  subcontinent  is  not  well 
documented ,but it seems to show geographical variation.LEC is generally rare 
in India as compared to South East Asian countries,with the exception of some 
northeastern  states,  mainly  Nagaland2.The  present  study   compares  the 
incidence ,age,sex distribution and relationship of EBV and LEC in sporadic 
cases of LEC from India with world statistics.  
Lymphoepithelial carcinoma is an undifferentiated neoplasm arising in 
the  nasopharyngeal  mucosa.  It  is  remarkable  for  the  striking  geographic 
difference in incidence as well as near consistent association with Epstein – 
Barr virus. LEC shows bimodal distribution with peaks in younger and older 
age groups. It shows male predominance. 
In  recent  years  histopathological  examination  requires  the  use  of 
accessory  diagnostic  methods  like  immunohistochemistry  which  detects  the 
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phenotype of tumors.It also helps in demonstrating the EBV virus association 
with lympho epithelial carcinoma in tissue sections.
 Immunohistochemistry  is  also  very  helpful  in  distinguishing 
lymphoepthelial Carcinoma from lymphoma when there is diagnostic difficulty 
in histopathology.
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AIMS AND OBJECTIVE
1. To study the prevalence of lymphoepithelial carcinoma 
2. To study the role of immunohistochemical markers in the diagnosis of 
lymphoepithelial carcinoma
3. To differentiate lymphoepithelial carcinoma as a distinct entity among 
other  carcinoma  with  intense  lymphocytic  infiltrations,  using  IHC 
markers and to treat accordingly
4. To demonstrate presence or absence of EBV antigen in lymphoepithelial 
neoplasms.
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REVIEW OF LITERATURE
DEFINITION
Lymphoepithelial carcinoma is an undifferentiated malignant neoplasm 
arising  from  the  nasopharyngeal  mucosa  that  show  evidence  of  squamous 
differentiation.  The  most  common  type  of  nasopharyngeal  tumor  is 
undifferentiated  nasopharyngeal  carcinoma,  which  is  remarkable  for  the 
striking geographic differences in its incidence as well as the near consistent 
association with Epstein-Barr virus.
Nasopharyngeal  carcinoma  is  also  the  prototype  of  a  family  of 
morphologically distinctive tumors – the lymphoepithelial carcinomas- that can 
arise in a variety of sites, head and neck mucosal sites, salivary gland, lung and 
thymus.
Interestingly, in contrast to nasopharyngeal carcinoma, lymphoepithelial 
like carcinomas occurring in these sites usually show a strong association with 
EBV only in Asians but not in Caucasions.3
SYNONYMS 
 Lympho epithelioma
 Lympho epithelioma like carcinoma
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 Undifferentiated carcinoma with lymphoid stoma
 Non keratinizing carcinoma
 Undifferentiated carcinoma
CLASSIFICATION OF NASOPHARYNGEAL CARCINOMA  In WHO 
Classification (1978)
 Squamous cell carcinoma (WHO type1)
 Non keratinizing carcinoma (WHO type 2)
 Undifferentiated carcinoma (WHO type 3)
In WHO Classification (1991)
 Squamaous cell carcinoma
 Non Keratinizing carcinoma
 Differentiated carcinoma
 Undifferentiated carcinoma
Lympho epithelioma like carcinoma was considered a morphologic variant 
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of undifferentiated carcinoma4. Use of numerical designation of WHO types 
1,2  and  3  was  eliminated.  The  current  WHO  classification,  maintains  the 
terminology of the 1991 classification, with the addition of category. -Basaloid 
squamous cell carcinoma.
The  term  lymphoepithelioma  was  introduced  in  1921  by  Regaud  of 
France and Schmincke of Germany to refer the undifferentiated carcinoma with 
an intense lymphocyte component.  Lymphoepithelioma is an undifferentiated 
carcinoma with intense lymphoid infiltrates which originally was described in 
nasopharynx5,6.
Tumors  with  the  same  morphologic  pattern  as  nasopharyngeal 
lymphoepitheliomas  occurring  outside  nasopharynx  are  called 
lymphoepithelioma like carcinoma.
These tumors have been described in a variety of organs, including the 
stomach, lung, salivary gland, thymus, urinary bladder, breast, esophagus, other 
head  and  neck  mucosal  sites,  vagina,  renal  pelvis,  thyroid  gland,  skin  and 
lung7,12
EPIDEMIOLOGY
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GLOBAL INCIDENCE AND MORTALITY 
LEC constitutes 0.6% of all cancers.  Incidence is higher in native 
and foreign  born  Chinese,  South  East  African  and North  Africans.  Highest 
incidence of NPC has long been observed in Hong Kong, where 1 in 40 men 
develop NPC before the age of 75 years13.
AGE AND SEX DISTRIBUTION
In higher risk groups, LEC incidence rises after the age of 30 years and 
peak at  40-60 years and there after declines .  Age distribution is  similar in 
males  and  females,  although  it  is  seen   2-3  folds  higher  in  men  than  in 
women14.
ETIOLOGY
* Inter play of genetic susceptibility
* Infection by Epstein- Barr virus
* Environmental  factors  (dietary  and  non  dietary)  in  disease 
causation
ESPTEIN- BARR VIRUS IN NASOPHARYNGEAL CARCINOMA
Near  constant  association  of  EBV  with  NPC,  irrespective  of  ethnic 
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background, indicates a probable oncogenic role of the virus in the generation 
of this tumor14. EBV is a member of the Sub family of herpes virus, a group of 
Lymphotrophic viruses that includes human herpes virus 8.
GENES RELEVANT IN TRANSFORMATION AND REPLICATION 
 Latent membrane proteins (LMP 1, LMP 2 A & LMP 2B)
 EBV nuclear antigens (EBNA-1, EBNA-2, EBNA-3A, EBNA 3B 
EBNA3C)
 EBV early RNAS (EBER 1 and 2)
 RNA originating from the Bann HIA site.
NPC was the first epithelial neoplasm to be linked with EBV,serological 
data suggested a correlation between increased EBV antibody titres and NPC16. 
Subsequently,  the  EBV  genome  was  identified  in  tumor  extracts15.  Nearly 
100% of non keratinizing NPC are positive by Insitu Hybridization for EBV 
encoded  EBER,  regardless  of  patient  ethnicity  or  geographic  location. 
Evidence of oncogenic role of the virus in the genesis of the tumor includes,
1.Raised levels of antibodies especially IgA against EBV in most patients 
with NPC compared with normal controls.
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2.Higher titres of IgA antibodies against EBV in patient with large tumor 
bulk.
3.Presence of EBV DNA or RNA in practically all tumor cells.
4.Presence of EBV in a clonal episomal form, indicating that the virus has 
entered the tumor cell before clonal expansion.
5.Presence of EBV in the precursor lesion of NPC but not in the normal 
nasopharyngeal epithelium. 
The evidence was considered sufficient to classify EBV as carcinogenic 
by  the  international  Agency  for  Research  on  Cancer  (1ARC)  in  199717. 
Increased  circulating  levels  of  EBV  DNA  are  associated  with  a  worse 
prognosis and active disease and may provide a method for assessing patient 
risk and monitoring treatment response. 
ENVIRONMENTAL FACTORS
Diet 
 Occurrence of  NPC is  higher  in   regions  were,  high  levels  of 
volatile nitrosamines are used in preserved food 18.
15
 Preserved or fermented food and Consumption of salted fish19 are 
seen  to be associated with higher incidence
OCCUPATIONAL EXPOSURE 
* Exposure to smoke, chemical fumes and dusts, 
* Formaldehyde exposure,
* Prior  radiation  exposure,  also  are  seen  to  be 
associated with higher risk of nasopharyngeal carcinoma.
LOCALIZATION
Most  common  site  of  origin  is  the  lateral  wall  of  the  nasopharynx 
especially the fossa of Rosenmuller, followed by the superior posterior wall. 
Other sites include head and neck mucosa, salivary gland, lung, thymus, uterus, 
urinary bladder, and esophagus .
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COMMON PRESENTING SYMPTOMS AND SIGNS OF 
NASOPHARYNGEAL CARCINOMA20
Presenting Features
Symptoms
FREQUENCY
(%)
Neck Mass
42%
Nasal (Post nasal drip, discharge, bleeding, 
obstruction)
46%
Aural (tinnitus, discharge, ear ache, 
deafness)
42%
Head ache 16%
Ophthalmic (double vision, squint, 
blindness)
6%
Facial numbness 5%
Speech/swallowing problem 2%
Weight Loss 4%
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PHYSICAL SIGNS
PRESENTING FEATURES FREQUENCY (%)
Enlarged neck nodes 72%
Bilateral neck nodes 35%
Neck nodes extending to supra clavicular fossa 12%
Cranial nerve palsy 10%
Deafness 3%
Dermatomyositis 1%
IMAGING
Magnetic Resonance (MRI) is the study of choice for assessing the loco-
regional  extent  and  intra  cranial  extension.  Computerized  Tomography  is 
useful in depicting cortical bone erosion.
SEROLOGICAL STUDIES
Positive serology against Epstein-Barr virus is found in close to 100% of 
patients  with  non-keratinizing  NPC21.Detection  of  1gA against  viral  capsid 
antigen  (VCA)  and  1gG/1gA  against  early  antigens  (EA)  are  the  most 
extensively used diagnostic tool.
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Newer antibody tests based on Recombinant EBV antigens such as EB 
nuclear   antigen  (EBNA),  membraneantigen  (MA),  thymidinekinase  (TK), 
DNApolymerase, DNAse and Z Tran activator protein (Z at) can be used in 
combination,
RELEVANT DIAGNOSTIC PROCEDURES 
 Complete physical  examination and endoscopic  examination of 
the nasopharyngeal region.
 Biopsies taken from the gross lesions.
 In the absence of a gross lesion multiple biopsies should be taken 
from the lateral. superior and posterior walls of nasopharynx for 
patients with high suspicion of NPC.
MACROSCOPY
The tumor can appear as a smooth bulge in the mucosa ,a discrete raised 
nodule  with or  without  surface ulceration or  a  frankly infiltrative fungating 
mass. Some times no grossly visible lesion is seen.
19
PATTERNS OF SPREAD
Primary
Inferior extension along the lateral pharyngeal walls and tonsillar pillars 
occur in almost one third of patients. Extension into the posterior nasal cavity is 
frequent  but  usually  limited  to  less  than  1  cm.  Invasion  of  the  Posterior 
ethmoids, the maxillary antrum, and the orbit occurs fairly often. Invasion into 
or  through  the  skull  base  is  recognized  radiographically.In  at  least  25% of 
patients the sphenoid sinus is frequently involved. Tumor may erode through 
the foreman ovale,  the foramen lacerum and the foramen spinosum. Tumor 
eventually reaches the cavernous sinus and has access to cranial nerves II and 
III.
LYMPHATIC SPREAD
There is an 80% to 90% incidence of metastatic neck node disease on 
presentation;  approximately  50%  of  patients  have  bilateral  lymphnode 
metastasis. NPC often metastasis to level V lymphnodes, Midline tumors often 
spread bilaterally.
HISTOPATHOLOGY
The  tumor  comprises  of  solid  sheets,  irregular  islands,  dyscohesive 
sheets and trabeculae of carcinoma cells intimately intermingled with variable 
numbers of  lymphocytes  and plasma cells.  Two patterns  of growth may be 
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seen,  some  times  in  combination  The  first,  referred  to  as  Regaud’s  type, 
consists of well defined aggregates  of epithelial cells surrounded by fibrous 
tissue and lymphoid cells.22 In the second, designated as Schmincke’s type, the 
neoplastic  epithelial  cells  grow diffusely  and  are  closely  intermingled  with 
inflammatory  cells.  The nuclei  of  NPC tend to  be  vesicular  with a  smooth 
outline and a single, large, eosinophilic nucleolus. 
CRITERIA FOR DIAGNOSING LYMPHOEPITHELIAL CARCINOMA 
OF NASOPHARNGEAL ORIGIN23
1.Primary  untreated  tumor  should  be  of  poorly  differentiated  carcinoma 
without keratin pearls, intra cellular bridges or individual cell keratinization.
2.Must exhibit either Schmincke or Regaud type of patterns and should be 
keratin positive by immunohistochemistry.
3.Tumor should be centered either in the region of the fossa of Rosenmuller or 
on the vault or posterior wall of the nasopharynx. 
EB VIRUS STATUS 
4.Positivity  for  EB virus  antibody titres  which should  be  raised  or  if  it  is 
normal EB virus moieties must be demonstrated in the tumor cells by Insitu 
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Hybridization for EB virus – encoded RNAS.
LYMPHOEPITHELIAL CARCINOMA OUTSIDE NASOPHARYNX
The histology of lymphoepithelial carcinoma outside nasopharynx is the 
same  as  that  of  lymphoepethelial  carcinoma  of  the  nasopharynx.  EBV 
association  is  less  or  lacking  in  most  of  the  sites  other  than  nasopharynx. 
However,  EBV  said  to  be  constantly  associated  with  lymphoepethelial 
carcinoma in 3 anatomical sites out side the nasopharynx, stomach, salivary 
gland and lung.
IMMUNO PROFILE IN LYMPHOEPITHELIAL CARCINOMA
Practically  all  tumor  cells  show  strong  staining  for  Pan-cytokeratin 
(AE1/AE3), MNF – 116). The staining for high molecular weight cytokeratins 
(Such as cytokeratins 5/6, 34 βe 12) is strong and staining for low molecular 
weight cytokeratins such as (CAM 5.2) in often weaker and sometimes patchy.
Cytokeratins  7  and  20  are  both  negative24.  In  differentiated  non 
keratinizing carcinoma the cytokeratin immunostain highlights the scanty wisps 
of cytoplasm that wrap around the large nucleus and extend outward as short 
narrow processes.  As a result of the cell nests being broken up by infiltrating 
lymphocytes,  a  distinctive  reticulated  or  meshwork  pattern  is  produced25,26, 
27, 28, 29.
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          Immuno reactivity for epithelial membrane antigen in nasophangeal 
carcinoma is often only focal. In most cases, the tumor exhibits strong nuclear 
staining  for  p63,  a  basal  cell  marker  that  mainly  highlights  the  basal  and 
parabasal cells of the overlying stratified squamous epithelium. The lymphoid 
cells  represent  a  mixture  of  T  cell  and  B  cells,  usually  with  the  former 
predominating  especially  within  and  around  the  tumor  islands.  At  least  a 
proportion of the T cells are activated cytotoxic T cells. The plasma cells are 
polyclonal.
There are variable numbers of scattered S100 protein positive dendritic 
cells. Some studies have reported the following features to be associated with a 
better prognosis.
 High density of dendritic cells
 High number of infiltrating lymphocytes
 Fewer number of granzyme B- positive cytotoxic cells.
EPSTEIN – BARR VIRUS DETECTION
Lymphoepithelial carcinoma of nasopharynx is associated with Epstein 
Barr virus in practically 100%, of cases, irrespective of the ethnic background 
of the patient. 
Latently  infected B cells  express  a  limited number of  EBV genes;  6 
nuclear  protein  (EBNA-1,  EBNA-2,  EBNA-34,  EBNA-3B,  EBNA-3C  and 
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EBNA – LP),
3 membrane proteins (LMP:-1, LMP-2A, and LMP-2B), EBV encoded small 
RNAS (EBER 1 and EBER 2) and RNA transcripts from the Bam HIA region.
Type I Latency: is characterized by expression of EBNA – 1 as well as 
the  RNA transcripts  for  EBER 1,  EBER 2  and the  Bam HIA region.  The 
presence  of  EBNA  1  is  the  minimal  expression  state  since  this  protein  is 
required for episomal replication and in its absence, the virus is not propagated. 
This type of latency has not been identified in either epithelial or mesenchymal 
neoplasms.
              In type II latency, LMP 1 and LMP 2 are expressed in addition to 
those of type I latency. 
Type  II  latency  is  seen  in  EBV  – associated  Hodgkin’s  lymphoma, 
peripheral  T/NK cell  lymphoma and undifferentiated NPC30,31.  LMP 1 is  an 
integral transmembrane protein that functions as a constitutively active member 
of the tumor necrosis factor receptor family.
LMP 1 potentiates a variety of signaling pathways including the nuclear 
factor κB, mitogen activated protein kinase, and phophotidylinositol 3-Kinase 
Alt Pathways32 and involves in angiogenesis which is the key step in tumor 
growth, invasion and metastasis.
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LMP 1 protein is essential for EBV  – mediated immortalization of B 
lymphocytes33 and  its  expression  has  been  shown  to  inhibit  the  terminal 
differentiation of keratinocytes, thus providing a possible explanation for the 
lack of differentiation of most EBV associated epithelial tumor cells.
             In addition to oncogenesis, LMP-1 is suggested to be relevant to the 
metastatic  property  of  NPC34,35&36.  Studies  also  report  that  LMP-1  positive 
NPCs show a  more progressive  attitude and an increased tendency towards 
lymph node metastasis than LMP-1 negative NPCs. Recent study71. suggests 
that induction of c-met proto-oncogene by LMP-1 in mediated by activation of 
Ets-1  transcription  factor  which  leads  to,  upregulation  of  cell  motility 
considered to be an essential factor in the multiple steps of metastasis.
To confirm, the association of EBV in a given tumor, the virus must be 
detected with in the tumor cells. EBV latent membrane protein-1 (LMP-1) is 
usually  positive in  only 30-40% cases37,38 and the immuno staining is  often 
patchy. How ever one recent study39 states that no biopsy is completely devoid 
of LMP-1 positive cells and also suggests the use of S12 antibody which is 
more sensitive in staining tissue sections than CS1-4 antibody.
              The nested PCR technique is one of the most powerful methods for 
identifying specific DNA fragments.  The simplest and most reliable way to 
demonstrate EBV is Insitu hybridization for EBV encoded early RNA (EBER) 
which is present in abundance in cells latently infected by EBV40-46.
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2002 AMERICAN JOINT COMMITTEE ON CANCER STAGING FOR 
NASOPHARYNGEAL CANCER
Primary Tumor (T)
T1 : Tumor confined to the nasopharynx
T2 : Tumor extends to soft tissues. 
T2a : Tumor extends to the oropharynx and/or Nasal cavity 
without parapharyngeal extension.
T2b : Any tumor with parapharyngeal extension.
T3 : Tumor involves bony structures and/or paranasal sinuses 
T4 : Tumor with intra cranial extension, infra temporal fossa, 
hypopharynx, orbit or masticator space.
REGIONAL LYMPHNODES (N)
NX Regional lymphnodes cannot be assessed.
N0 No regional lymphnode metastasis
N1 Unilateral metastasis in lymphnode (S) 6cm or less in 
greatest dimension, above the supraclavicular fossa
N2 Bilateral metastasis in lymphnode (S) 6cm or less in greatest 
dimension, above the supraclavicular fossa.
N3a Metastasis in a lymphonode (S) greater than 6 cm
N3b Extension to the supraclavicular fossa.
STAGE GROUPING
O Tis No Mo
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I T1 No Mo
II A T2G No Mo
II B T1 N1 Mo
T2a N1 Mo
T2b N0 – N1 Mo
2III T1 N2 Mo
T2a – T2b N2 Mo
T3 N0 – N2 Mo
IV A T4 N0 – N2 Mo
IV B Any T N3 Mo
IV C Any T Any N M1
PROGNOSIS
The presenting stage is  the  most  important  prognostic  factor.  5  Year 
Disease specific survival for stage I is 98%. Stage II A-B 95% stage III 86% 
and stage IV A-B 73%.  
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Younger age and female patients are associated with better prognosis47. 
Tumor volume may prove to be useful for predicting local control. Circulating 
plasma/serum EBV DNA is a more promising prognostic factor. 
Higher  titers  are  associated  with  advanced  stages48.  High  density  of 
dendritic  cell,  high  number  of  infiltrating  lymphocytes  and  low number  of 
granzyme B-Positive cytotoxic cells are associated with better prognosis25,29. 
Aneuploid status or high pretreatment tumor proliferative fraction, co-rrelate 
significantly with poor survival.
28
IMMUNOHISTOCHEMISTRY
GENERAL CONCEPTS OF IMMUNOHISTOCHEMISTRY 
 Immunohistochemistry  is  a  method for  localizing  specific  antigens  in 
tissues or cells based on antigen – antibody recognition. IHC has a long history, 
extending to more than half a Century from 1940 when Coons developed an 
Immunofluoresence  technique  to  detect  corresponding  antigen  in  frozen 
sections49. However only since the early 1990 has the method found general 
application in surgical pathology.
A  series  of  technical  developments  in  IHC  have  created  sensitive 
detection  systems.  Among  them  is  the  enzymatic  label  (Horse  radish 
peroxidase) developed by Avrameas and Colleagues50 which in the presence of 
suitable  colorigenic  substrate  systems,  allowed  visualization  of  the  labeled 
antibody by light microscopy.
One  of  the  critical  issues  in  the  development  of  immuno peroxidase 
techniques  was  related  to  the  need  to  achieve  greater  sensitivity  from  the 
simplest one step direct conjugate method to multi step detection techniques 
such as the peroxidase – Antiperoxidase, Avidin- biotin Conjugate and Biotin 
Streptavidin methods, together with amplification methods and highly sensitive 
polymer based labeling systems51.
The  development  of  the  Hybridoma  technique  facilitated  the 
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development  of  IHC  and  the  manufacture  of  abundant  highly  specific 
monoclonal antibodies, many of which found early application in staining of 
tissues,  Only  when the  IHC became applicable  to  routinely  formalin  fixed, 
paraffin embedded tissue sections did it bring in the “brown revolution”. The 
critical significance of rendering the IHC technique suitable for routine paraffin 
sections was illustrated by Taylor and colleagues, who in 1974, showed that it 
was possible to demonstrate antigens in routinely processed tissue.
Enzyme  digestion  was  introduced  by  Huang  and  colleagues  as  a 
pretreatment to IHC staining to unmask some antigens that had been altered by 
formalin fixation. However the enzyme digestion method, while widely applied 
did not improve IHC staining of the majority of antigens as perceived by Leong 
and colleagues.
Another drawback of enzymes digestion was that it has proved difficult 
to control the optional digestion condition for individual tissue sections when 
stained with different antibodies. The difficulties in standardization provided a 
powerful incentive for the development of a new technique.
The  Antigen  retrieval  (AR)  technique52 was  developed  by  Shi  and 
associates  in  1991.  In  contrast  to  enzyme  digestion  the  AR technique  is  a 
simple method that involves heating routinely processed paraffin sections at 
high temperatures before  staining procedures.  The intensity of IHC staining 
was increased dramatically after AR Pretreatment, as demonstrated by various 
articles53.
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BASIC PRINCIPLES OF IMMUNOHISTOCHEMISTRY
The object of all stains is to recognize micro chemically the existence 
and  distribution  of  substances  which  we  have  been  made  aware  of  macro 
chemically.  The  basic  principle  of  IHC  as  with  any  other  special  staining 
method is a sharp localization of target components in the cell and tissue based 
on a significant signal – to – noise ratio.  Amplifying the signal, while reducing 
the non specific background staining (noise) is the major strategy to achieve a 
satisfactory and practically useful result.
An  antibody  is  a  molecule  that  has  the  property  of  combining 
specifically  with  a  second  molecule,  termed  the  antigen.  Antigen-antibody 
recognition is based on the three dimensional structure of protein or antigen, 
which is a critical issue in the understanding of the effectiveness of IHC as well 
as the mechanisms of AR.
The term epitope corresponds to a cluster of aminoacid residues that 
bind specifically to the paratope of an antibody. An epitope is a functional unit 
and not the structural element of a protein and may be classified as continuous 
and discontinuous. The former are compounds, of a continuum of residues in a 
polypeptide chain, where as the latter consist of residues from different parts of 
a  polypeptide  chain,  brought  together  by  the  folding  of  the  protein 
conformation.
The  development  of  the  Hybridoma  technique  provided  an  almost 
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unlimited source of highly specific antibodies, although monoclonal antibodies 
do not guarantee antigen specificity, Different antigens may share similar or 
cross  reactive  epitopes,  and  the  practical  specificity  reflected  by  IHC  is 
excellent for most monoclonal antibodies tested.
In contrast a polyclonal antibody is in fact an antiserum, which contains 
several different molecular species of antibody having varying affinities and 
even  varying  specificities  against  the  different  antigens  or  antigenic 
determinants. As a result polyclonal antibodies may give the most non specific 
background  staining  in  slides  than  the  staining  obtained  using  monoclonal 
antibodies.
Comparison  of  sensitivity  and  specificities  between  polyclonal  and 
monoclonal antibodies indicate that polyclonal antibody may be more sensitive 
but less specific than monoclonal antibody. The reason may be that polyclonal 
antibody may recognize several different epitope on a single antigen whereas a 
monoclonal  antibody recognizes  only  a  single  type  of  epitope.Sophisticated 
amplification techniques, coupled with use of the AR technique have reduced 
the practical importance of this distinction. 
          Although the specificity of monoclonal antibody has been questioned 
regarding  cross  reactivity  with  non-target  molecules,  most  community 
available  monoclonal  antibodies  are  highly  reliable  for  IHC,  but  again  the 
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ultimate specificity control should be the observation of the expected pattern of 
staining in control tissue sections, with the corresponding lack of unexpected or 
inexplicable staining reactions53, 54.
TISSUE  FIXATION,  PROCESSING  AND  ANTIGEN  RETRIEVAL 
TECHNIQUES
The ideal fixative for IHC studies should not only be readily available 
but should also be in widespread use to maximize the range and number of 
samples  available  for  IHC  studies.  The  fixative  should  preserve  antigen 
integrity  and  should  limit  extraction,  diffusion  or  displacement  of  antigen 
during  subsequent  processing.  It  should  also  give  good  preservation  of 
morphological details after embedding in a supporting medium.
Common fixatives used in Histopathology are divided into two groups, 
coagulative  fixatives  such  as  ethanol  and  cross  linking  fixatives  such  as 
formaldehyde.  Both  types  of  fixatives  cause  changes  in  the  stearic 
configuration  of  proteins  which  may  mask  epitopes  and  adversely  affect 
bonding with antibody.
In most surgical pathology laboratories the fixative used is 10% neutral 
buffered formalin. Traditionally non cross linking fixatives are believed to be 
superior to aldehyde fixation in order to retain immuno reactivity for certain 
33
larger protein such as intermediate filaments and immunoglobin.
ADDITIONAL ADVANTAGES OF FORMALIN INCLUDE
1. Good morphological preservation.
2. Cheap.
3. Sterilizes tissues.
4. Carbohydrate antigens are better preserved.
5. Many antigens are preserved during the process of cross linking.
Formalin  may  be  regarded  as  a  satisfactory  fixative  for  both 
morphology and IHC provided that  a  simple and effective AR technique is 
available to recover those antigens that are diminished or modified.
              Subsequent treatment with absolute ethanol during dehydration serves 
as double fixation.
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ANTIGEN RETRIEVAL
The  disadvantage  of  masking  of  antigens  during  fixation  can  be 
overcome  by  antigen  retrieval  technique.  Process  involves  unmasking  of 
antigens by one of these four techniques:
1. Proteolyte enzyme digestion
2. Microwave antigen retrieval
3. Microwave and trypsin antigen retrieval technique.
4. Pressure Cooker antigen retrieval.
Trypsin enzyme digestion is difficult to control.
A  Simple  heat  induced  AR  technique  is  now  widely  applied  in 
pathology. Successful application of the AR technique for routine IHC Staining 
of  formalin  fixed  tissue  has  rendered  the  search  for  alternative  fixatives  to 
replace  formalin  less  urgent.  In  AR technique  involving  heat,  the  result  is 
influenced by heating condition (temperature) and time of heating) and PH  of 
the AR Solution. High temperature is the most important factor.
Microwave AR technique is a new technique. Heating is done in plastic 
coplin jars. Drying of sections can take place and hence careful monitoring is 
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required. Pressure cookers do not require close inspection and do not suffer 
from inconsistent results. In any of the conditions where in heat is employed 
slides are coated with silane to prevent loss of sections.
Among the Various solutions, citrate buffer at pH 6.0, EDTA at pH 8.0 
and TRIS- EDTA at PH 9.9 or 10.0 are most popular
Both  microwaves  and  pressure  cookers  with  or  without  additional 
enclosures  for  temperature  control  and  moisture  are  used  successfully  for 
retrieval of antigens like cytokeratin55. 
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MATERIAL AND  METHODS
The  study  was  conducted  from  the  period  of  2006-2009  both 
prospectively  &  retrospectively.  All  the  biopsy  samples  received  in  the 
Department of Pathology, Stanley Medical College, were analysed. Total of 57 
cases with malignant lesions showing prominent lymphoepitheial component 
were  taken for  the  study.  All  samples  taken  from nasopharynx were  given 
special reference.
Epithelial  malignances  showing  rich  lymphoplasmacytic  infiltrations 
were taken for analysis. Samples routinely processed and stained with H&E 
were analysed followed by IHC markers.  Epithelial  and lymphoma markers 
were  used  to  confirm  the  histopathological  diagnosis  of  lymphoepithelial 
carcinoma.
LMP-1 immunohistochemical marker was used to demonstrate EBV in 
tissue  sections.  Lymphoepitheial  carcinoma  reported  at  Kilpauk  Medical 
College, Madras Medical College, and Government Royapettah Hospital were 
also included for the study purpose.
INCLUSION CRITERIA
Tumors  which  were  diagnosed  as  lymphoepithelial 
carcinoma/lymphoma  and   poorly  differentiated  carcinoma  with  lymphoid 
aggregates were included.
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EXCLUSION CRITERIA
Tumors which were diagnosed histopathologically as well differentiated 
and  moderately  differentiated  squamous  cell  carcinoma  and  other  benign 
tumors were excluded.
METHOD OF DATA COLLECTION
The material consisted of 57 cases whose clinical details were obtained. 
Out  of  57 cases,  34 were lymphoepithelial  carcinoma,  21cases  were poorly 
differentiated  carcinoma,  2  cases  had  doubtful  histological  diagnosis  and 
reported as lymphoepithelial carcinoma/lymphoma for which IHC was done for 
confirmation.
METHOD OF TISSUE PREPARATION FOR IHC
10% buffered neutral formalin were used for fixation of specimens. The 
tissues  were  processed  in  automated  histokinette  through  various  grades  of 
alcohol and xylol. Paraffin blocks were prepared; Sections were cut using Semi 
automatic Microtome with disposable blades and stained with hemotoxylin and 
eosin .Suitable sections were chosen for IHC.
Slides wee coated with chrome alum, and subjected to AR using the 
Microwave  technique  with  TRIS –EDTA buffer  solution  .Slides  were  then 
treated by HRP (Horse radish peroxidase) polymer technique.
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HRP POLYMER TECHNIQUE
The coated slides were taken through the following steps
1. Treatment  with  peroxidase  block  –  for  incubation  of  endogenous 
peroxidase in the tissue for 20 minutes, washed in TRIS buffer for 5 
minutes.
2. Application of power block O- to block non specific antigen – antibody 
reactions for 20 minutes. The excess power block was blot dried. 
3. Application of Primary antibody – Murine antibodies for 60 minutes. 
Washed in TRIS buffer for 5 minutes.
4. Application  of  super  enhancer  for  30  minutes  which  increased  the 
sensitivity  of  antigen -antibody reaction thereby enhancing the  final 
reaction product.
5. Application  of  SS  label  –  Secondary  antibody  from  goat  with  the 
tagged  horse  radish  peroxidase  enzyme  for  30  minutes.  Washed  in 
TRIS buffer.
6. Application of DAB (Diamino benzidine) Chromogen for 5 minutes – 
which was cleared by the enzyme to give the colored product at antigen 
sites. Washed in distilled water for 5 minutes.
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7. The slides were then counter stained with hematoxylin .Slides were air 
dried and mounted with DPX (Distrene dibutyl pthalide in Xylol)
IHC MARKERS USED
PHENOTYPIC MARKERS
            Pan cytokeratin  and leukocyte  common antigen were used for 
confirming the histopathological diagnosis in all undifferentiated carcinoma. 
CD20, CD3 were additionally used in doubtful cases to rule out lymphoma.
SPECIFIC MARKER 
Latent  membrane  protein  -1  (CS1-4  antibody)  was  used  in  all 
cytokeratin positive cases. Section of Hodgkin lymphoma was taken as control 
for LMP-1 (Fig 21,22).Immuno-staining was scored on the basis of  positive 
tumor  cells  and  the  relative  immunostaining  intensity.Five  consecutive 
microscopic fields were analyzed. 
The  following  grading  system  was  adapted  to  score  the  number  of 
positive cells:
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Scoring method39
 0-none  seen in the section
 1-presence of rare positive cells  but not exceeding 25%
 2-26 to 50% positive cells 
 3-51 to 75% positive cells
 4-76 to 100% positive cells
IMMUNOSTAINING INTENSITY
 0-none
 1-weak
 2-moderate
 3-intense
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OBSERVATION AND RESULTS
Out of 57 biopsy specimens which were diagnosed as lymphoepithelial 
carcinoma/ lymphoma were taken for the study. 
These included,
 34 cases of undifferentiated carcinoma (Fig 1-8)
 21 cases of poorly differentiated carcinoma 
 2 cases whose histopathological  diagnoses were doubtful  and 
needed immunohistochemistry for confirmation.
Immunohistochemistry  was  done  using  pancytokeratin  and  leukocyte 
common antigen  on  34  cases  of  undifferentiated  carcinoma  to  confirm  the 
histopathological  diagnosis.33  cases  were  found  to  be  positive  for 
pancytokeratin. (Fig 12,13,17) and CD 45, CD20,CD3 were found to positive 
in infiltrating lymphocytes. (Fig 14,15,16,18,19 and 20 )
25  cases  of  pancytokeratin  positive   undifferentiated  carcinoma  were 
selected for  latent  membrane protein  -1  immunostaining for  detecting  EBV 
association
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AGE DISTRIBUTION OF LYMPHOEPITHELIAL CARCINOMA
TABLE - 1
Years No of cases
10 to 20 9
21 to 30 2
31 to 40 4
41 to 50 6
51 to 60 5
61 to 80 8
Total 34
Majority  of  cases  belonged to  younger  age group (10-20) and 61-80 
years of age showing a bimodal distribution.
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AGE DISTRIBUTION OF LYMPHOEPITHELIAL CARCINOMA
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SEX DISTRIBUTION  
Out of 34 cases 23 were male patients and 11 were female patients.
SITE DISTRIBUTION OF CASES
Majority of cases (24) were found in the nasopharynx,  2 cases were in 
pyriform fossa, 2 cases were in posterior one third of tongue. Rest of the case 
were  found  in  Nasal  cavity  (1)  tonsil  (1),  hypopharynx  (1),  epiglottis  (1), 
esophagus (1), salivary gland (1), larynx (1).
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TABLE - 2
Site No of cases
Nasopharynx 24
Esophagus 1
Salivary gland   1
Nasal cavity 1
Larynx 1
Posterior 1/3  of Tongue  1
Tonsil 1
Pyriform fossa  2
Hypopharynx 1
Epiglottis 1
                         Total 34
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SITE DISTRIBUTION OF CASES
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CLINICAL PRESENTATION 
Most  of  the  cases  presented  with  nasal  symptoms  like  nasal 
obstruction,discharge  per  nose  (29  cases)  .  3  cases  presented  with  cervical 
lymphnode as the initial manifestation,for which FNAC was done and reported 
as LEC/lymphoma.2 cases presented with swallowing/speech problem 
TABLE - 3
Presenting features - Symptoms Frequency
Neck Mass 8%
Nasal (Post Nasal drip, discharge, 
bleeding obstruction)
83%
Speech /swallowing problem 6%
Head ache 3%
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CLINICAL PRESENTATION
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IMMUNOHISTICHEMISTRY RESULTS
TABLE - 4
S.
No
Biopsy 
No.
Site HPE CK
Lymphoma 
Panal
LMP-1
1 7281/06 nasopharynx LEC + focal intense
2 7545/06 nasopharynx LEC negative negative
3 815/07 Esophagus LEC + focal negative
4 983/07 Post.1/3 tongue LEC + focal moderate
5 1607/07 nasopharynx LEC + focal weak
6 516/08 nasopharynx LEC + focal weak
7 731/08 Pyriform fossa LEC + focal weak
8 1356/08 nasopharynx LEC + Focal intense
9 1438/08 nasopharynx LEC + focal weak
10 2740/08 hypopharynx LEC + focal negative
11 2743/08 nasopharynx LEC + focal Weak
12 2774/08 nasopharynx LEC + focal intense
13 2890/08 nasopharynx LEC + focal Moderate
14 3085/08 nasopharynx LEC + focal moderate
15 3553/08 epiglottis LEC + focal negative
16 4598/08 Salivary gland LEC + focal intense
17 4621/08 stomach LEC /poorly
Differentiated
Carcinoma
+ diffuse negative
18 4825/08 Soft palate LEC + focal negative
19 5055/08 tonsil LEC/lympho
ma
negative positive -
20 5063/08 larynx LEC + focal negative
21 8414/08 nasopharynx LEC + focal moderate
22 101/09 nasopharynx LEC + focal moderate
23 2789/09 tonsil LEC + focal negative
24 2834/09 nasopharynx LEC + focal moderate
25 4939/09 nasopharynx LEC + focal moderate
4939/09 Cervical node Metastatic/ly
mphoma
negative positive negative
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Latent  membrane  protein  -1  expression  in  tumor  cells 
Immunohistochemistry  using  the  anti  LMP-1  antibody  resulted  in  highly 
heterogeneous staining between tumors from different patients. It was assessed 
using  a  scoring  system  based  on  the  percentage  of  positive  cells  and  the 
intensity of staining. (Fig 22, 23, 25, 26, 27, 28)
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SCORING METHOD
 0-none  seen in the section
 1-presence of rare positive cells  but not exceeding 25%
 2-26 to 50% positive cells 
 3-51 to 75% positive cells
 4-76 to 100% positive cells
IMMUNOSTAINING INTENSITY
 0-none
 1-weak
 2-moderate
 3-intense
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CLINICAL CORRELATION OF LMP-1 WITH AGE OF THE 
PATIENTS
TABLE - 5
Age
LMP-1
Intense moderate
weak
10 to 30 3 2 1
40 to 60 1 2 3
More than 60 years - 1 -
               Younger age group showed higher levels of expression.
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CLINICAL CORRELATION OF LMP-1 WITH AGE OF THE 
PATIENTS
                                         
CLINICAL  CORRELATION  OF  LMP-1  WITH  SITE  OF 
OCCURRENCE 
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LEC  from  nasopharynx  showed  strong  expression  of  LMP-1  when 
compared to  LEC from other sites except salivary gland. 
TABLE - 6
Site LMP-1
Nasopharynx 13
Posterior  1/3 of tongue 1
Pyriform fossa 1
Salivary gland 1
CLINICAL CORRELATION OF LMP-1 WITH SITE OF 
OCCURRENCE
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TUMORS  IN  WHICH  IMMUNOHISTOCHEMISTRY  HELPED  IN 
CONFIRMING THE DIAGNOSIS
CASE 1
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           Excision specimen of a laryngeal mass which presented with obstructive 
symptoms in a 60 year old male was received . Histopathological examination 
revealed a neoplasm arranged in diffuse sheets with interspersed lymphocytes. 
High power view showed pleomorphic cells  with vesicular  nuclei.  Some of 
them showed prominent nucleoli. (Fig 37 ) 
          Considering the differential diagnosis of LEC and lymphoma, IHC was 
done using pan-cytokeratin and lymphoma panel .CD 45, CD20 (Fig 38) was 
found to be positive and CD3 and pan cytokeratin were negative.
            With IHC showing CD45, CD20 positivity, this case was confirmed to 
be Large B cell lymphoma.
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TABLE - 7
IHC markers Results
Pancytokeratin Negative
CD45 Positive
CD20 Positive
CD3 Negative
CASE - 2
                Total gatrectomy specimen which presented abdominal fullness in a 
60 year old female was received . Histopathologically the neoplasm showed 
sheets of  poorly differentiated cells  with dense lymphoid stroma.
IHC was done with pan cytokeratin ,and lymphoma panel .cytokeratin 
was  positive  in  tumor  cells  and  CD45,CD20,CD3  were  positive  in  non 
neoplastic  lymphocytes  .This  case  was  again  stained  with  latent  membrane 
protein -1, and it was found to be negative.
                Studies showed that LEC of gastric mucosa was strongly associated 
with EBV virus56,57.  Since LMP-1 was found to positive in only 30-40% of 
cases  as per previous studies, further molecular studies are needed for EBV 
detection in this  case.
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                                                    TABLE - 8
IHC markers Results
Pan cytokeratin Positive
CD45 Positive in non neoplastic lymphocytes
CD20 Positive in non neoplastic lymphocytes
CD3 Positive in non neoplastic lymphocytes
LMP-1 Negative
     
CASE - 3
67 years old male patient presented with nasal obstruction and cervical 
neck  node.  ENT  examination  revealed  a  nasopharyngeal  mass  .Biopsy 
specimens from both the sites examined histopathologically.
             Nasopharyngeal mass showed feature of undifferentiated carcinoma of 
nasopharynx (Fig 31, 32). IHC was done with pancytokeratin and lymphoma 
markers (CD45, CD20, CD3). Pan cytokeratin was found to be positive, (Fig 
34) and CD45, CD20, CD3 were positive in non neoplastic lymphocytes.
Sections  from  cervical  node  revealed  monotonous  population  of 
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lymphoid cells with out epithelial differentiation (Fig 35) showing completely 
different morphology in contrast to the primary nasopharyngeal mass. IHC was 
done, using pancytokeratin, CD45, CD20, CD3. CD45, CD20 (Fig 36) were 
positive in the lymphoid cells and pancytokeratin and CD3 were negative.
Both the sections were again stained with latent membrane protein-1 and 
it  was  found  to  be  positive  in  only  in  nasopharyngeal  mass  (Fig  35)  and 
negative in cervical node .Finally this case was reported as EBV associated 
lymphoepithelial carcinoma, with associated  small lymphocytic lymphoma –
cervical lymphnode .
TABLE - 9
IHC markers LEC SLL
Pancytokeratin positive negative
CD 45 Focal Positive
CD 20 focal Positive
CD 3 Focal negative
LMP-1 positive negative
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DISCUSSION
Nasopharyngeal  carcinoma  is  often  difficult  to  diagnose  because  of 
nonspecific nature of its clinical symptoms and the difficulty in visualizing the 
nasopharynx58.  Submucosal  primary  lesions  often  escape  endoscopic 
examination(59).Most of the tumors remain undiagnosed until they present as 
metestasis  to  cervical  lymph  nodes,often  without  overt  pathology  at  the 
primary site60. FNAC will be very much helpful in such cases60,62. One such 
case was diagnosed with FNAC ,in cervical node and it correlated with HPE 
diagnosis (Fig 9, 10) .
Koppiker et. al, have reported that 5 yr actuarial disease free survival of 
Indian patients is 13%61 which indicates the need for an early diagnosis and 
treatment  strategies  to  improve  survival.  Early  detection  of  NPC  should 
improve  cure  rate  and  reduce  morbidity  and  metastasis.  This  requires  an 
effective screening system.
Ethnic and regional factors are found to strongly influence the risk of 
disease. However ,there have been very few well conducted study on Indian 
patients64.  The  present  study  assess  the  age  distribution,  sex  distribution  , 
relationship  between  EBV and  sporadic  Indian  NPC and  the  role  of  latent 
membrane protein -1 in NPC detection.
 Out of 34 cases of lympho epithethelial carcinoma 9 cases were found 
in the younger age group (10 – 20) yrs and 8 cases in the older age group (61 
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-80) yrs Balakrishnan et.al63 observed bimodal age distribution with peaks in 
age group 15-24 and 45-54 yrs from India. 
This  present  study  confirms  the  bimodal  distribution  except  for  the 
increase in peak in 60-80 yrs of age group in contrast to 45-54 age group in the 
study of Balakrishnan et. al .  This study also confirms the male preponderance 
of lymphoepithelial  carcinoma as in  previous studies.
Most of the patients in this study, presented with nasal obstruction and 
nasal bleeding (83%). Three of them presented with cervical node metastasis as 
the initial manifestation.
Among 34 cases were undifferentiated carcinoma, 23 cases were found 
in  nasopharynx,  2  cases  in  pyriform  fossa.  Rest  of  them  were  found  in 
hypopharynx , nasal cavity, larynx, tonsil, salivary gland  and esophagus.
Immunohistochemistry  was  done  with  pancytokeratin   and  leukocyte 
common antigen to confirm the histopathological diagnosis, 2 cases were found 
to be positive for lymphoma panel and reported as lymphoma.
Pancytokeratin  positive  cases  were  selected  for  immunostaining  with 
latent membrane protein- 1 and it was found that LMP-1 was associated with 
79% of the cases with nasopharyngeal origin.These results are consistent with 
Raab-Traub et al and Chang et al64, 65.
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Of  LEC  among  other  sites,  salivary  gland  LEC  showed  strong 
association with LMP -1, LEC in pyriform fossa and posterior 1/3 of tongue 
showed weak and moderate  staining  pattern  respectively.LEC in  other  than 
these sites showed negative results  which are consistent with Bijan Khademi et 
al76 indicating LMP-1 association is more specific for LEC of nasopharyngeal 
origin.
This present study also shows that higher level of LMP-1 expression 
was associated with  younger  age group (75%).  Thus confirming the  earlier 
study by Abdelmajid Khabir et al39
As per  literature  LMP 1  potentiates  a  variety  of  signaling  pathways 
including  the  nuclear  factor  kb,  Mitogen  activated  protein  kinase,and 
phophotidylinositol  3  –Kinase  Alt  pathways  and  involver  is  angiogenesis 
which is a key step in tumor growth and invasion and metastasis65, 66, 67.
LMP-1  protein  in  essential  for  EBV-mediated  immortalization  of  B 
lymphocytes  and  its  expression  has  been  shown  to  inhibit  the  terminal 
differentiation of keratinocytes, thus providing a possible explanation for the 
lack of differentiation of most EBV associated epithelial tumor cells.68
In addition to oncogenesis,  LMP-1 is  suggested to be relevant to the 
metastatic property of NPC72. Studies  also report that LMP-1 positive NPCs 
show  a  more  progressive  attitude  and  an  increased  tendency  towards 
lymphnode  metastasis  than  LMP-1  negative  NPCs  ,Studies  suggest  that 
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induction  of  c-met  proto-oncogene  by  LMP-1 in  mediated  by  activation  of 
Ets-1  transcription  factor  which  leads   to  upregulation  of  cell  motility 
considered to be an essential factor in the multiple steps of metastasis.69,74
In this present study 2 cases presented with cervical node metastasis, 
were associated with high levels of LMP-1 expression. Also a 13 year old boy 
with LEC who presented with vertebral region metastasis within one year of 
the diagnosis of the primary tumor and was also found to be associated with 
high levels of LMP-1 expression.
Interestingly, according to Padhamanathan and collegues75 LMP-1 was 
detected in all preinvasive NPCs that quickly developed into invasive NPCs. 
Thus LMP-1 mediated enhancement of metastatic potential could be an early 
event in NPC, although regulation of LMP-1 expression in NPC remains to the 
elucidated.
To confirm, the association of EBV in a given tumor, the virus must be 
detected with in the tumor cells. EBV latent membrance  protein -1 (LMP-1) in 
usually positive in only 30-40% cases. It is usually less sensitive and specific 
than other molecular analysis. 
However Abdel Majiid Khabir et al observed in his study that no biopsy 
is completely devoid of LMP-1 positive cells and he also suggested the use of 
S12 antibody which  is  more  sensitive  in  staining tissue  section than  CSI-4 
antibody.  In  this  present  study  we  used  CSI-4  antibody  for  detecting  the 
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presence  of  EBV in  tissue  sections.  This  might  be  the  reason for  LMP -1 
negative LEC of nasopharynx in this study.
Dietz et al concluded that tyramid augmented IHC for LMP-1 staining 
was  found  to  be  clearly  positive  in  samples  previously  showed  negative 
staining  with  conventional  IHC.  Both  the  studies  showed  100%  LMP-1 
expression.
TABLE - 10
Reference Year of study No.of LMP-1 positive samples
Tumor tissue 
source
Plaza et al(43) 2002 13/30 Paraffin block
Dietz et al(77) 2004 33/33 Paraffin block
G Bar Sela et 
al(78)
2004 6/45 Paraffin block
Abdel majiid et al 2005 29/29 Paraffin block
Present study 2009 15/25 Paraffin block
Despite the limitations of LMP-1, its simplicity, applicability to paraffin 
sections and its use as an indicator of progressiveness of the tumor has made it 
an  attractive  ancillary  method  for  early  diagnosis  of  lymphoepithelial 
carcinoma.Metastatic potential of LEC might be reduced by inhibition of the 
LMP-1 mediated signaling pathways.
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SUMMARY AND CONCLUSION
During the period of study from May 2006 to September 2009 tumors 
which were diagnosed as undifferentiated carcinoma (34 cases) were taken up 
for study.
LEC of nasopharynx showed bimodal distribution with peaks in 10-20 
years and 60-80years of age group.
There was a male predominance as previous studies  
Nasopharynx was the commonest site for LEC.
Cytokeratin has proved to be the most specific and sensitive marker for 
confirming LEC.
All cytokeratin positive cases again stained with LMP-1.79% of LEC 
were found to be associated with LMP-1 expression.
LEC of nasopharyngeal origin showed strong association with EBV than 
LEC of other sites.
Younger age group showed higher levels  of LMP-1 expression. Also 
patients  who  presented  with  metastasis,  showed  higher  levels  of  LMP-1 
expression, thus adding weight to the metastatic potential of LMP-1 expression.
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